Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STADOL PRESERVATIVE FREE vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Management of pain (moderate to severe),Preoperative or preanesthetic medication,Supplement to balanced anesthesia,Relief of pain during labor
Relief of moderate to moderately severe pain
0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal elimination half-life is 2.5–3.3 hours in adults; prolonged to 4–6 hours in elderly or hepatic impairment.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized in the liver to hydroxylbutorphanol via CYP3A4 and other enzymes.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily hepatic metabolism (glucuronidation) to inactive metabolites; renal excretion accounts for <5% unchanged drug. Approximately 70% of dose excreted in urine as metabolites, 20% in feces.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Approximately 76–80% bound to serum proteins, primarily albumin and α1-acid glycoprotein.
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Volume of distribution is 1.2–1.7 L/kg, indicating extensive tissue distribution.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Intramuscular: 70–80%; Subcutaneous: similar to IM. Oral: <5% due to extensive first-pass metabolism.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
For GFR 15–29 m L/min: reduce dose by 50% or increase dosing interval to every 6–8 hours. For GFR <15 m L/min: use with caution, reduce dose by 75% or administer every 8–12 hours. Hemodialysis: no supplemental dosing; not dialyzable.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% or extend interval to every 6 hours. Child-Pugh Class C: avoid use; if necessary, reduce dose by 75% and monitor closely.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Children ≥12 years: 0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed. Children 2–12 years: 0.1–0.2 mg/kg/dose intravenously or intramuscularly every 3–4 hours as needed (max single dose 2 mg). Children <2 years: not recommended.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Elderly patients (≥65 years): initiate at 0.5 mg intravenously or intramuscularly every 4–6 hours; increase cautiously based on response and tolerability. Reduce total daily dose by 25–50% compared to younger adults.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and risk of abuse and dependence.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Concomitant use with CNS depressants (e.g., benzodiazepines) increases risk of sedation, respiratory depression, coma, and death,Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients,Physical and psychological dependence with chronic use,May increase intracranial pressure in patients with head injury,Risk of hypotension in hypovolemic patients,May impair ability to perform hazardous tasks,Use in renal or hepatic impairment requires dose adjustment
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Known hypersensitivity to butorphanol or any component,Patients with significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
No significant food interactions. Avoid alcohol consumption.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Pregnancy Category C. First trimester: No adequate studies; potential risk based on animal data at 2.5-5 times human dose. Second trimester: Same as first; prolonged use may lead to neonatal opioid withdrawal syndrome. Third trimester: Risk of neonatal respiratory depression if administered near term; may cause opioid withdrawal in newborn after chronic use.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Excreted in human milk in low concentrations; M/P ratio not established. American Academy of Pediatrics considers butorphanol compatible with breastfeeding. Caution with high doses or prolonged use due to potential for neonatal drowsiness or withdrawal.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
No specific dose adjustments established; pharmacokinetics may be altered (increased volume of distribution, decreased peak concentrations). Use lowest effective dose for shortest duration; avoid during labor if alternative available due to risk of neonatal respiratory depression.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Stadol (butorphanol) preservative-free is for IV/IM use only; not intended for epidural or intrathecal administration due to potential neurotoxicity from the formulation. Onset of analgesia is rapid (within minutes IV). Butorphanol has ceiling effect on respiratory depression, making it safer than full mu agonists in equianalgesic doses. It can cause dysphoric reactions, especially in opioid-naive patients. Use with caution in patients with hepatic or renal impairment.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
This medication can cause drowsiness, dizziness, or lightheadedness; avoid driving or operating heavy machinery until you know how it affects you.,Do not drink alcohol or take other central nervous system depressants (e.g., benzodiazepines, other opioids) while using this medicine.,Report any severe nausea, vomiting, confusion, or hallucinations to your healthcare provider.,Butorphanol can be habit-forming; use only as prescribed.,If you are pregnant, plan to become pregnant, or are breastfeeding, inform your doctor before use.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STADOL PRESERVATIVE FREE vs ANEXSIA, answered by our medical review team.
STADOL PRESERVATIVE FREE is a Opioid Analgesic that works by Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STADOL PRESERVATIVE FREE and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STADOL PRESERVATIVE FREE is: 0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STADOL PRESERVATIVE FREE and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STADOL PRESERVATIVE FREE is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; potential risk based on animal data at 2.5-5 times human dose. Second trimester: Same as first; prolonged use may lead t. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.